Treatment with exenatide, a GLP-1 receptor agonist, was comparable to placebo in slowing the rate of Parkinson’s disease progression over 96 weeks of treatment, according to a phase 3 study published in The Lancet.

WEDNESDAY, Feb. 5, 2025 (HealthDay News) -- Hopes that GLP-1 drugs such as Ozempic and Wegovy could help slow Parkinson's disease have taken an hit. A new study found that a drug in the same class called exenatide, marketed as Byetta, had no effect on slowing the disease or easing its symtoms.

Semaglutide, the drug used in Ozempic, has been linked to lowering the risk of Alzheimer's disease in the past. So, it was natural for the scientists to be hopeful when they tested the possibility of an Ozempic-like drug to improve Parkinson's disease symptoms,

The FDA approved an apomorphine hydrochloride infusion device (Onapgo) to treat motor fluctuations in adults with advanced Parkinson's disease, Supernus Pharmaceuticals announced on Tuesday. The wearable device is the first subcutaneous apomorphine infusion device for Parkinson's and provides continuous treatment during the day, Supernus noted.

The GLP-1 drug, exenatide, has no positive impact on the movement, symptoms or brain imaging of people with Parkinson's, finds a new study led by UCL researchers.